CXC chemokine ligand 12 (CXCL12) via its cognate receptor (CXCR4) controls the chemotaxis of multiple myeloma cell line (U266) via PI3K/AKT, PLCβ3, RhoA, NFκB and ERK1/2

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 22, 2011, Pages 2505-2512

  Badr, Gamal ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

Author keywords

Chemotaxis; CXCL12; Flow cytometry; Multiple myeloma; Western blot

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C BETA3; PLERIXAFOR; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SN 50; STROMAL CELL DERIVED FACTOR 1; WORTMANNIN;

ARTICLE; CELL MIGRATION; CELL SURFACE; CHEMOTAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84155174749     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP11.682     Document Type: Article

References (49)

1. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha U (2007). Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood, 109: 2714-2715.
2. Badr G, Borhis G, Treton D, Moog C, Garraud O, Richard Y (2005). HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL) 20, and CCL21. J. Immunol., 175(1): 302-10.
3. Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, Lapree G, Tsapis A, Richard Y (2008). BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood, 111(5): 2744-54.
4. Baggiolini M, Dewald B, Moser B (1994). Interleukin-8 and related chemotactic cytokines- CXC and CC chemokines. Adv. Immunol., 55: 179-197.
5. Balkwill F (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol., 14, 171-179.
6. Barbieri F, Bajetto A, Porcile C, Pattarozzi A, Massa A, Lunardi G, Zona G, Dorcaratto A, Ravetti JL, Spaziante R (2006). CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation. Ann. N Y Acad. Sci., 1090, 332-343.
7. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF (2005). Defective p38 mitogen-activated protein kinase signaling impairs chemotactic but not proliferative responses to stromal-derived factor-1 in acute lymphoblastic leukemia. Cancer Res., 65:3290-3298.
8. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 394: 894-897.
9. Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Riet I (2003). Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell produced monocyte chemotactic proteins MCP-1, -2 and -3. British J. Cancer, 88: 855-862.
10. Butcher EC, Picker LJ (1996). Lymphocyte homing and homeostasis. Science, 272:60-272:66.
11. Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N (2003). Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology, 110: 421-426.
12. Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J. Bone Miner. Res., 24 (7):1150-61.
13. Evanthia T. Roussos, John S. Condeelis and Antonia Patsialou (2011). Chemoaxis in cancer. Nature Rev. Cancer., 11: 573-587.
14. Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, Fadeel B, Zheng C (2010). The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol. Immunol., 47(14): 2388-96.
15. Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A (1998). Reduced tumoricity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol., 161: 342-346.
16. Floridi F, Trettel F, Di Bartolomeo S, Ciotti M. T, Limatola C (2003). Signaling pathways involved in the chemotactic activity of CXCL12 in cultured rat cerebellar neurons and CHP100 neuroepithelioma cells. J. Neuroimmunol., 135, 38-46.
17. Florio T, Casagrande S, Diana F, Bajetto A, Porcile C, Zona G, Thellung S, Arena S, Pattarozzi A, Corsaro A (2006). Chemokine stromal cell-derived factor 1alpha induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals. Mol. Pharmacol., 69, 539-546.
18. Frade JM, Mellado M, Del Real G, Gutierrez-Ramos JC, Lind P, Martinez AC (1997). Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J Immunol 159: 5576-558.
19. Hideshima T, Chauhan D, Hayashi T (2002). The biological sequelae of stromal cell-derived factor-1a in multiple myeloma. Mol. Cancer Ther., 1: 539-44.
20. Hoshino Y, Hatake K, Kasahara T, Takahashi Y, Ikeda M, Tomizuka H, Ohtsui T, Uwai M, Mukaida N, Matsushima K (1995). Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages into tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow. Exp. Hematol., 23: 1035-1039.
21. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T (2000). Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res., 6, 3530-3535.
22. Kucia M, Jankowski K, Reca R (2004). CXCR4- SDF-1 signaling, locomotion, chemotaxis and adhesion. J. Mol. Histol., 35: 233-245.
23. Kurihara T, Warr G, Loy J, Bravo R (1997). Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med., 186: 1757-1762.
24. Lataillade JJ, Clay D, Bourin P, Herodin F, Dupuy C, Jasmin C (2002). Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G (0)/G (1) transition in CD34 (+) cells: evidence for an autocrine/paracrine mechanism. Blood, 99: 1117-29.
25. Lee CK, Wang S, Huang X, Ryder J, Liu B (2010). HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett., 296(2):233-40.
26. Luster AD (1998). Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 338: 436-445.
27. Mellado M, Rodriguez-Frade JM, Aragay A, Del Real G, Martin AM, Vila-Coro AJ, Serrano A, Mayor F, Martinez C (1998). The chemokine monocyte chemotactic protein 1 triggers Janus Kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J. Immunol., 161: 805-813.
28. Menu E, Asosingh K, Indraccolo S (2006). The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM model. Haematologica, 91: 605-12.
29. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G (2003). Expression and function of chemokine receptors in human multiple myeloma. Leukemia, 17: 203-210.
30. Mowafi F, Cagigi A, Matskova L, Bjork O, Chiodi F, Nilsson A (2008). Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation. Pediatr. Blood Cancer, 50: 812-817.
31. Murooka TT, Ward SE, Fish EN (2005). Chemokines and cancer. Cancer Treat. Res., 126, 15-44.
32. Nagasawa T, Kikutani H, Kishimoto T (1994). Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. USA; 91: 2305-9.
33. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O (2003). Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol., 170: 1136-1140.
34. O-charoenrat P, Wongkajornsilp A, Rhys-Evans PH, Eccles SA (2004). Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. Int. J. Cancer, 20; 111(2): 174-83.
35. Peters W, Dupuis M, Charo IF (2000). A mechanism for the impaired IFNgamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J. Immunol., 165: 7072-7077.
36. Pinto LA, Williams MS, Dolan MJ, Henkart PA, Shearer GM (2000). Beta-chemokines inhibit activation-induced death of lymphocytes from HIV-infected individuals. Eur. J. Immunol., 30, 2048-2055.
37. Rossi D, Zlotnik A (2000). The biology of chemokines and their receptors. Annu. Rev. Immunol., 18: 217-42
38. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000). Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood, 96: 34-40.
39. Sotsios Y, Whittaker GC, Westwick J, Ward SG (1999). The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. J. Immunol, 163: 5954-5963.
40. Spiegel A, Kollet O, Peled A (2004). Unique SDF-1- induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood, 103: 2900-2907.
41. Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Hayasaka H, Miyasaka M (2005). Chemokines in tumor progression and metastasis. Cancer Sci., 96: 317-22.
42. Turner L, Ward SG, Sansom D, Westwick J (1996). A role for RANTES in T lymphocyte proliferation. Biochem. Soc. Trans., 24, 93S.
43. Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H, Sato M (2003). Possible role of stromal- cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp. Cell Res., 290: 289-302.
44. Van de Broek I, Leleu X, Schots R (2006). Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica, 91: 200-206.
45. Van de Broek I, Vanderkerken K, Van Camp B, Van Riet I (2008). Extravasation and homing mechanisms in multiple myeloma. Clin Exp. Metastasis., 25(4): 325-34.
46. Van Riet I, Van Camp B (1993). The involvement of adhesion molecules in the biology of multiple myeloma. Leuk. Lymphoma., 9: 441-52.
47. Vecchi A, Massimiliano L, Ramponi S, Luini W, Bernasconi S, Bonecchi R, Allavena P, Parmentier M, Mantovani A, Sozzani S (1999). Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J. Leukoc. Biol., 66: 489-494.
48. Zeelenberg IS, Ruuls-Van Stalle L, Roos E (2003). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res., 63: 3833-3839.
49. Urbinati G, Audisio D, Marsaud V, Plassat V, Arpicco S, Sola B, Fattal E, Renoir JM (2009). Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model. Pharm. Res., 27(2): 327-339.